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Introduction {#sec1}
============

The organ size, determined by the number and size of cells in the organ, is regulated by genetic and environmental factors ([@bib10], [@bib37]). The size of bones determines the height, build, and stability of the skeleton, while the quality of bones, defined by bone matrix and mineral contents and microstructures, determines the bone strength ([@bib47]). It is estimated that peak bone mass accounts for 60% of the risk of osteoporosis ([@bib2]). The maximal bone size, mass, and strength are reached in humans at the age of 23--24 years and in mice at 10--12 weeks ([@bib3], [@bib14]). Bone growth and remodeling are carried out by coordinated osteoblastic bone formation and osteoclastic bone resorption ([@bib22], [@bib28]). Osteoblasts (OBs) are derived from bone marrow-mesenchymal stromal cells (BM-MSCs), which can self-renew and differentiate into OBs, chondrocytes, or adipocytes, whereas osteoclasts (OCs) are derived from monocytes ([@bib12], [@bib18], [@bib30]). Proliferation of stem cells and progenitors increases the pool of OBs or OCs, while proper maturation determines the activities of these cells. Bone size, mass, and quality can be regulated by the growth hormone-insulin growth factor (IGF) axis, nutrition, steroid hormones, vitamin D, and mechanical stimuli ([@bib3], [@bib21], [@bib41], [@bib52]). It is generally believed that IGFs promote OB and chondrocyte proliferation and differentiation, which mediate the anabolic effects of IGFs on bone growth ([@bib4], [@bib5], [@bib48]).

The mammalian target of rapamycin (mTOR) pathway is the sensor of growth factors, including IGF1, macrophage colony-stimulating factor (M-CSF), and nutrients ([@bib19], [@bib32]), and is expected to play critical roles in bone growth spurt during adolescence. Activated mTOR increases global protein synthesis to promote cell proliferation ([@bib25], [@bib26]). In humans, tuberous sclerosis complex (TSC) patients carry mutations in one allele of *TSC1* or *TSC2*, encoding negative regulators of mTOR, and they develop benign tumors in multiple organs due to loss of heterozygosity of the *TSC* genes ([@bib32]). In addition, TSC patients develop focal sclerotic bone lesions ([@bib1], [@bib34], [@bib38], [@bib44]). In mouse, *mTor* ablation or mTOR activation by ablation of *Tsc1* or *Tsc2* causes embryonic or neonatal lethality ([@bib32]). Studies of mice with *Tsc1* or *Tsc2* deleted in committed OBs or chondrocytes established roles for mTOR signaling in bone mass accrual and endochondral ossification ([@bib23], [@bib39]), with the cartilage studies being limited to embryos or newborns due to survival problems of the mice ([@bib7], [@bib49]). Yet, the roles for mTOR signaling in bone size and quality control during adolescent growth, especially from the angle of the stem cells of the skeleton, remain largely unknown.

Here, we ablated *Tsc1* in BM-MSCs and monocytes, as well as in their progenies, OBs and OCs, and found that mTOR regulates bone size in length and width by coordinating MSC proliferation and differentiation, and bone quality by suppressing osteoclastogenesis and bone resorption in cell-autonomous manners and by regulating the expression of OPG and RANKL by MSCs. The bone phenotypes induced by *Tsc1* ablation mediated by *Prx1-Cre* or *LysM-Cre* were largely rescued by treatment with rapamycin, an mTOR inhibitor. Analysis of the TSC patients from the Han Chinese population revealed that more than 90% of the patients show increased focal bone density, which is associated with a decrease in bone resorption marker and an increase in bone formation marker. These findings thus uncover multifaceted roles for mTOR signaling in regulating bone size and quality, and underscore the decisive contribution of suppression of bone resorption to the achievement of peak bone mineral contents.

Results {#sec2}
=======

The mTOR Pathway Was Activated in Multiple Locations of the Bone during Adolescent Growth {#sec2.1}
-----------------------------------------------------------------------------------------

mTOR can be activated by growth factors and nutrients. We found that in femurs of 1-day-old, 4-week-old, or 8-week-old mice, mTOR activation, manifested by S6 phosphorylation, was detectable in the proliferation and prehypertrophic zones of the growth plate ([Figures 1](#fig1){ref-type="fig"}A--1C), which are involved in longitudinal bone growth, the region underneath the growth plate, where trabecular bones are formed, and the periosteal and endosteal surfaces, which are responsible for bone radial growth ([Figures 1](#fig1){ref-type="fig"}A--1C). Staining of both p-S6 and Col2 or Osx confirmed that mTOR activation occurred in chondrocytes and OBs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). p-S6 signals were reduced in 8-week-old mouse bones compared with those in 1-day-old and 4-week-old mice, suggesting that mTOR is highly activated during adolescent growth. Moreover, starvation inhibited mTOR activation, whereas feeding activated mTOR on mouse bone sections ([Figures 1](#fig1){ref-type="fig"}D--1F), confirming that food intake or nutrients can activate mTOR in the bone.Figure 1mTOR Was Activated in the Bone during Adolescent Growth and by Feeding(A--C) Immuno-staining of p-S6 on bone sections of 1-day-old (A), 4-week-old (B), or 8-week-old mice (C). The femur bones were decalcified and embedded in paraffin. Antibodies against p-S6 and secondary antibodies conjugated with horseradish peroxidase were used to detect the signal.(D--F) Starvation inhibited mTOR activation, whereas feeding activated mTOR on bone sections. P1 pups were starved overnight (D) by separating from the mother and then euthanized 2 hr (E) or 8 hr (F) after feeding. The femur bones were frozen sectioned and stained for p-S6. Scale bars, 200 μm (A--F left panels) and 50 μm (A--F right panels).

*Prx1-Cre; Tsc1*^*f/f*^ Mice Showed Shorter and Thicker Long Bones and Joint Defects {#sec2.2}
------------------------------------------------------------------------------------

It has been reported that *mTor* ablation in BM-MSCs causes mouse neonatal lethality ([@bib7]). To further test the physiological function of mTOR activation in bone growth, we deleted *Tsc1* in BM-MSCs by crossing floxed *Tsc1* mice with *Prx1-Cre* mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B) ([@bib35], [@bib36]). Our previous studies have confirmed that Prx1 marks stromal cells with tri-lineage differentiation potentials and labels cells at the growth plate, trabecular region, and periosteal surface ([@bib9]). Western blot and immunohistochemical analysis confirmed that *Tsc1* was largely deleted in BM-MSC cultures and on bone sections, leading to an increase in p-S6 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). The *Tsc1*-deficient mice were born at the expected Mendelian ratio and showed unaltered body weight and length compared with wild-type (WT) littermates ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

Micro-computed tomography (CT) analysis showed that the length of the long bones of the *Tsc1*-deficient mice was decreased compared with control littermates of the same gender at 2.5 months of age ([Figures 2](#fig2){ref-type="fig"}A and 2B), when peak bone mass is achieved in mice. Histological analysis revealed that the mutant mice showed an increase in the height of growth plates and the size of chondrocytes compared with control mice ([Figure 2](#fig2){ref-type="fig"}C). The chondrocyte proliferation zone and hypertrophy zone were not clearly separated in the mutant mice ([Figure 2](#fig2){ref-type="fig"}C), likely due to disruption of the coordination between chondrocyte proliferation and differentiation. The mutant mice also showed a defect in articular cartilage and joint formation ([Figure 2](#fig2){ref-type="fig"}D). A similar perichondrium and cartilage anomaly has been reported in hereditary multiple exostoses patients, a disorder caused by mutations in *EXT1* and *EXT2* ([@bib24], [@bib27]), yet we found that mTOR activation did not alter the protein levels of EXT1 or EXT2 in MSCs, chondrocytes, or cartilage ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C).Figure 2Ablation of *Tsc1* in *Prx1+* MSCs but Not in *Dermo1+* or *Osx+* OBs Led to Shortened but Broadened Limbs and Joint Deformation(A) Micro-CT images of the femur bones and the vertebrae (L3 and L4) of 2.5-month-old *Prx1-Cre; Tsc1*^*f/f*^, *Dermo1-Cre; Tsc1*^*f/f*^, and *Osx-Cre; Tsc1*^*f/f*^ mice. Upper panel, coronal plane of femur; middle panel, transverse plane of femur; bottom panel, vertebrae.(B) Quantitation data showed that the length of *Prx1-Cre; Tsc1*^*f/f*^ mouse long bones was decreased compared with control mice. N = 15 mice.(C) H&E staining of the growth plates of 2.5-month-old *Prx1-Cre; Tsc1*^*f/f*^ and control mouse femur bones. Right panel: quantitation data of the diameter of chondrocytes. Scale bars, 200 μm (left panel) and 20 μm (middle panel). N = 3 mice (6 views each).(D) H&E staining of the sections of the knee joint of *Prx1-Cre; Tsc1*^*f/f*^ and control mice. Scale bars, 200 μm (upper panel) and 20 μm (lower panel).(E) Quantitation data showed that the width of the *Prx1-Cre; Tsc1*^*f/f*^ mouse femur bones was increased compared with control mice. N = 6 mice.(F) Quantitation data showed that the width of growth plates of *Prx1-Cre; Tsc1*^*f/f*^ mouse femur bones was increased compared with control mice. N = 6 mice.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

On the other hand, the mutant mice showed an increase in the width of femurs and physeal growth plate ([Figures 2](#fig2){ref-type="fig"}A, 2E, and 2F). It is believed that, in addition to periosteal bone apposition, the width of the growth plate is an important factor determining the width of long bones ([@bib45]). These results indicate that TSC1 plays an important role in bone growth in both length and width, although in opposed ways.

It has been reported that TSC1 also activates mTOR-independent pathways such as RAF and NOTCH. We found that in BM-MSCs, *Tsc1* deletion did not affect the protein levels of RAF or the activation of its downstream ERK kinases ([Figure S2](#mmc1){ref-type="supplementary-material"}D). *Tsc1* deficiency slightly increased the protein levels of NOTCH1 ([Figure S2](#mmc1){ref-type="supplementary-material"}D), which may mediate the effect of mTOR activation on OB differentiation ([@bib23]). To determine whether the skeletal phenotypes observed in *Prx1-Cre; Tsc1*^*f/f*^ mice are caused by mTOR activation, we treated the mutant and control mice with rapamycin and found that rapamycin inhibited skeletal growth in WT mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3M), as reported previously ([@bib49]). Moreover, rapamycin largely rescued the skeletal phenotypes including bone width/length, bone mass, trabecular bone number, trabecular separation, the growth plate height, the size of chondrocytes, and the joint development anomaly in *Prx1-Cre; Tsc1*^*f/f*^ mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3M). These results indicate that mTOR signaling downstream of TSC1 deficiency plays an important role in bone growth.

The change in bone size and joint formation defects observed in *Prx1-Cre; Tsc1*^*f/f*^ mice are not reported in mice with *Tsc1* or *Tsc2* ablated in OBs ([@bib7], [@bib23], [@bib39]). Moreover, these defects were not obvious in *Prx1-Cre; Tsc1*^*f/f*^ embryos or p1 newborn mice. The *Prx1-Cre; Tsc1*^*f/f*^ embryonic skeletons (E18.5) appeared normal and the length of the long bones of day 1 pups was not significantly affected ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). The p1 pups did not develop the joint problem either ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These results suggest that the bone size alteration and joint defects observed in *Prx1-Cre; Tsc1*^*f/f*^ adult mice are developed during adolescent growth.

*Prx1-Cre; Tsc1*^*f/f*^ Mice Showed Increased Bone Volume but Decreased Bone Mineralization {#sec2.3}
-------------------------------------------------------------------------------------------

Micro-CT analyses revealed that the mutant mice showed an increase in the thickness of cortical bones and the volume and thickness of trabecular bones ([Figures 3](#fig3){ref-type="fig"}A--3C), accompanied by a decrease in the number of trabecular bones and bone separation ([Figures 3](#fig3){ref-type="fig"}D and 3E). Bone histomorphometry revealed that the 2.5-month-old mice showed an increase in bone formation rate but a decrease in bone mineralization rate ([Figures 3](#fig3){ref-type="fig"}F and 3G), suggesting that bone mineralization might be impeded even though bone formation is increased.Figure 3Ablation of *Tsc1* in MSCs Increased Bone Mass but Reduced Bone Quality(A) Ablation of Tsc1 in *Prx1+* MSCs increased the cortical thickness of femur bones to a greater extent than ablation of *Tsc1* in *Dermo1+* or *Osx+* OBs. N = 4 mice.(B) Micro-CT analysis revealed that *Prx1-Cre; Tsc1*^*f/f*^ mice showed a greater increase in trabecular bone volume than *Dermo1-Cre; Tsc1*^*f/f*^ and *Osx-Cre; Tsc1*^*f/f*^ mice. N = 4 mice.(C--G) *Prx1-Cre; Tsc1*^*f/f*^ mice showed an increase in thickness (C) and the number (D), and a decrease in separation (E) of trabecular bones, and an increase in bone formation rate (BFR) (F) and mineral apposition rate (MAR) (G). N = 4 mice.(H) *Prx1-Cre; Tsc1*^*f/f*^ mice femur cortical bones appeared to be porous, some of which were stained positive for CD31. Black arrow, pores; red arrow, blood vessel. Scale bars, 200 μm (upper panel) and 50 μm (lower panel).(I) von Kossa staining of *Prx1-Cre; Tsc1*^*f/f*^ and control littermates showed that the mineralization was impeded in the mutant mouse bones. Scale bar, 200 μm.(J) Masson staining of *Prx1-Cre; Tsc1*^*f/f*^ and control littermates showed that the mineralization was impeded in the mutant mouse bones. Scale bar, 50 μm.(K) *Prx1-Cre; Tsc1*^*f/f*^ mice showed reduced bone strength, judged by the three-point bending experiment results. N = 4 mice.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

We found that the cortical bones appeared to have quality problems. Firstly, they were porous, accompanied by an increase in the number of blood vessels, as CD31, a marker for endothelial cells, could stain these pores ([Figure 3](#fig3){ref-type="fig"}H). Secondly, von Kossa staining and H&E staining showed that the mutant bone was rich in osteoids that were not fully mineralized ([Figures 3](#fig3){ref-type="fig"}I and 3J). The mineralization defects are similar to what have been reported in mice with *Tsc1* or *Tsc2* ablated in OBs, which were rescued by rapamycin treatment ([@bib7], [@bib23], [@bib39]). Thirdly, the bones were more fragile than WT bones, based on three-point bending experiments ([Figure 3](#fig3){ref-type="fig"}K). These results, taken together, indicate that mTOR activation by ablation of *Tsc1* in *Prx1*+ MSCs inhibits bone mineralization, disrupts bone microstructure, and reduces bone strength, thus lowering the bone quality.

mTOR Activation Regulated Bone Size and Mass Mainly via MSCs but Not OBs {#sec2.4}
------------------------------------------------------------------------

To determine the contributions of mTOR signaling in MSCs and OBs to the bone phenotypes observed in *Prx1-Cre; Tsc1*^*f/f*^ mice, we ablated *Tsc1* in *Dermo1*+ MSCs and *Osx*+ OBs, respectively. Dermo1 is believed to be expressed in BM-MSCs after Prx1, while Osx is expressed in committed OBs after Runx2 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) ([@bib40], [@bib51]). Western blot analysis of BM-MSCs and differentiated OB cultures confirmed that *Tsc1* was largely deleted, leading to an increase in p-S6 ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We found that these two mouse lines showed normal body weight and body length ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F).

X-ray imaging analyses revealed that unlike *Prx1-Cre; Tsc1*^*f/f*^ mice, the length and the width of the femurs and the growth plates were not significantly altered in *Dermo1-Cre; Tsc1*^*f/f*^ mice or *Osx-Cre; Tsc1*^*f/f*^ mice compared with their control littermates ([Figures 2](#fig2){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}G and data not shown). These two mouse lines showed an increase in trabecular bone volume and cortical bone thickness, with the increase in *Dermo1-Cre; Tsc1*^*f/f*^ mice being greater than that in *Osx-Cre; Tsc1*^*f/f*^ mice ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S4](#mmc1){ref-type="supplementary-material"}H--S4J). The increase in trabecular bone volume and cortical bone thickness in these two mouse lines were much less than those of *Prx1-Cre; Tsc1*^*f/f*^ mice ([Figures 2](#fig2){ref-type="fig"}A, [3](#fig3){ref-type="fig"}A, and 3B). These results collectively suggest that mTOR signaling regulates trabecular and cortical bone mass mainly via MSCs.

We also compared the vertebrae (L3 and L4) of the three *Tsc1*-deficient mouse lines against their respective control littermates using micro-CT, and found that the bone mineral contents were not significantly altered in *Prx1-Cre; Tsc1*^*f/f*^ mice or *Osx-Cre; Tsc1*^*f/f*^ mice, whereas *Dermo1-Cre; Tsc1*^*f/f*^ mice showed a modest increase in bone mineral contents ([Figure 2](#fig2){ref-type="fig"}A).

*Tsc1* Deficiency Increased the BM-MSC Pool but Inhibited MSC Differentiation {#sec2.5}
-----------------------------------------------------------------------------

We found that on bone sections of *Prx1-Cre; Tsc1*^*f/f*^ mice, the number of Ki67-positive cells was greatly increased in the growth plate ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}H). The heights of the Ki67-positive proliferation zone and the Col10-positive hypertrophic zone were increased ([Figure S4](#mmc1){ref-type="supplementary-material"}H), suggesting that the balance between proliferation and differentiation of chondrocyte progenitors were disrupted by *Tsc1* ablation. In addition, the number of OBs per bone surface was significantly increased ([Figure 4](#fig4){ref-type="fig"}B). *Prx1-Cre; Tsc1*^*f/f*^ mouse bone marrow also contained an increased number of colony-forming units, an indicator of the number of MSCs ([Figure 4](#fig4){ref-type="fig"}C), suggesting that the pool of MSCs was expanded.Figure 4*Tsc1*^*−/−*^ MSCs Showed Increased Proliferation, but Defective Osteogenic and Chondrogenic Differentiation(A) Ki67 staining of femur bones of *Prx1-Cre; Tsc1*^*f/f*^ and control mice. Right panel: quantitation data. Scale bars, 200 μm (left panel) and 50 μm (middle panel). N = 3 mice (6 views each).(B) *Prx1-Cre; Tsc1*^*f/f*^ mice showed an increase in the number of OBs in the trabecular region. N = 8 mice.(C) *Prx1-Cre; Tsc1*^*f/f*^ mice showed an increase in the number of bone marrow colony-forming units (CFU). Right panel: quantitation data. N = 4 independent experiments.(D) *Prx1-Cre; Tsc1*^*f/f*^ BM-MSCs showed a decrease in OB differentiation, judged by ALP and von Kossa staining, a decrease in chondrocyte differentiation, judged by Alcian blue staining, but normal adipocyte differentiation. Scale bar, 100 μm.(E) qPCR results revealed that *Tsc1*^*−/−*^ MSCs showed a decrease in the expression of osteogenic and chondrogenic markers. N = 4 independent experiments.(F) *Tsc1*^*−/−*^ MSCs showed decreased activation of β-catenin. BM-MSCs were isolated from *Prx1-Cre; Tsc1*^*f/f*^ and control mice, cultured for 3 days, and then harvested for western blot analysis.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

*Tsc1*^*−/−*^ BM-MSCs showed a defect in chondrogenic differentiation, manifested by a decrease in Alcian blue staining and expression of chondrocyte marker Sox9, a defect in OB differentiation, manifested by a decrease in the expression of ALP and OB markers such as *Runx2*, *Osx*, and *ColIα*, and mineralization, without affecting MSC adipogenesis ([Figures 4](#fig4){ref-type="fig"}D and 4E). Therefore, *Tsc1* deficiency disrupted the balance between MSC proliferation and differentiation.

A previous study has shown that depletion of *Tsc1* in differentiated chondrocyte by *Col2-Cre* led to a defect in chondrocyte differentiation ([@bib49]), which was shown to be mediated by an altered PTHrP-IHH loop ([@bib29], [@bib33]). We also found that Tsc1 depletion resulted in an increase in the mRNA levels of *Pthrp*, but not *Ihh*, in MSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Our results support the notion that mTOR regulates chondrocyte differentiation via PTHrP ([@bib49]).

We also looked at the major signaling pathways that control MSC osteogenic differentiation and found that *Tsc1* deficiency in MSCs decreased β-catenin activation without significantly affecting the activation of Smad1/5/8 or p38 MAPK ([Figures 4](#fig4){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}F). Since Wnt-β-catenin is a master regulator of OB differentiation, these results suggest that mTOR may regulate MSC osteogenic differentiation via compromising the Wnt-β-catenin pathway ([@bib23]). We also checked the β-catenin-independent pathways activated by Wnt molecules such as Wnt5a ([@bib50], [@bib16]), and found that *Tsc1* deletion led to a modest decrease in JNK activation, a downstream signaling molecule of Wnt5a, without affecting the expression of Wnt5a ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). The effects of the non-canonical Wnt pathways warrant further investigation.

Ablation of *Tsc1* in MSCs but Not OBs Showed Suppressed Osteoclastogenesis and Bone Resorption {#sec2.6}
-----------------------------------------------------------------------------------------------

We then stained for TRAP-positive OCs on femur bones and found that *Prx1-Cre; Tsc1*^*f/f*^ mice showed a decreased number of OCs ([Figure 5](#fig5){ref-type="fig"}A). Bone histomorphometry analysis confirmed that the mutant mice showed a decrease in bone erosion surface and the number of OCs, which were rescued by rapamycin treatment ([Figures 5](#fig5){ref-type="fig"}B and 5C and data not shown). Furthermore, *Prx1-Cre; Tsc1*^*f/f*^ mice showed a decrease in urine deoxypyridinoline (DPD) levels, an in vivo bone resorption marker ([Figure 5](#fig5){ref-type="fig"}D). On the other hand, *Dermo1-Cre; Tsc1*^*f/f*^ and *Osx-Cre; Tsc1*^*f/f*^ mouse lines did not show a change in the number of TRAP-positive OCs ([Figure 5](#fig5){ref-type="fig"}A). These results indicate that *Tsc1* deficiency in MSCs, but not in OBs, suppresses osteoclastogenesis, which may help to promote bone mineral accrual.Figure 5Ablation of *Tsc1* in *Prx1*+ MSCs but Not in *Dermo1*+ or *Osx*+ OBs Suppressed Osteoclastogenesis and Bone Resorption(A) TRAP staining of bone sections revealed that femurs of *Prx1-Cre; Tsc1*^*f/f*^ mice, but not *Dermo1-Cre; Tsc1*^*f/f*^ or *Osx-Cre; Tsc1*^*f/f*^ mice showed a decrease in the number of OCs in vivo. Scale bar, 50 μm. Data are from three independent experiments.(B--D) *Prx1-Cre; Tsc1*^*f/f*^ mice showed a decrease in bone erosion surface (B) (N = 8 mice), the number of OCs (C) (N = 8 mice), and the levels of urine DPD (D) (N = 4 mice).(E) *Tsc1*^*−/−*^ MSCs showed altered expression of *Rankl*, *M-Csf*, and *Opg*. N = 4 independent experiments.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

To understand how mTOR signaling regulates the coupling between MSCs and osteoclastogenesis, we analyzed the mRNA levels of *Rankl*, *Opg*, and *M-Csf* in *Tsc1*^*−/−*^ and control BM-MSCs and found that *Tsc1* deficiency greatly increased the expression of *Opg* and decreased the expression of *Rankl* ([Figure 5](#fig5){ref-type="fig"}E). Similar results were obtained from immuno-staining for RNAKL and OPG on bone sections and measurement of RANKL and OPG in the bone marrow ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). These results suggest that mTOR in BM-MSCs might regulate OPG and RANKL expression to suppress osteoclastogenesis and bone resorption. In addition, *M-Csf* expression was upregulated in *Tsc1*-deficient MSCs ([Figure 5](#fig5){ref-type="fig"}E). We showed that decreased M-CSF production by MSCs compromised proliferation of OC progenitor cells in co-culture experiments ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Ablation of *Tsc1* in Monocytes or OCs Increased Bone Mineral Contents {#sec2.7}
----------------------------------------------------------------------

The above studies showed that mTOR signaling in MSCs regulated bone growth in size and volume via MSCs and that *Tsc1* deletion in MSCs also led to a decrease in bone mineralization. Although mTOR activation in MSCs regulates the expression of OPG and RANKL to suppress bone resorption and increase bone mineral contents, this turns out to be inadequate to keep up with bone growth in size.

We then ablated *Tsc1* in monocytes, the OC progenitors, using *LysM-Cre* mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B) ([@bib8]), to test whether mTOR signaling in monocytes might affect adolescent bone mineral content accretion ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The mutant mice were born at the Mendelian ratio and they had unaltered body weight, body length, and femur radius and length ([Figures 6](#fig6){ref-type="fig"}A and 6B and data not shown).Figure 6Ablation of *Tsc1* in *LysM*+ Monocytes or *Ctsk*+ OCs Led to a Decrease in Bone Resorption(A) Micro-CT images of the femur bones and the vertebrae (L3 and L4) of *LysM-Cre; Tsc1*^*f/f*^ mice, *Ctsk-Cre; Tsc1*^*f/f*^ mice, and their respective control mice. N = 3 mice.(B) The length of femur bones of *LysM-Cre; Tsc1*^*f/f*^ mice (left panel) and *Ctsk-Cre;Tsc1*^*f/f*^ mice (right panel) were not altered compared with those of control mice. N = 6 mice.(C) *LysM-Cre; Tsc1*^*f/f*^ mice (upper panel) and *Ctsk-Cre; Tsc1*^*f/f*^ mice (lower panel) showed an increase in the trabecular bone volume. Right panel: quantitation data. N = 4 mice.(D) *LysM-Cre; Tsc1*^*f/f*^ mice (left panel) and *Ctsk-Cre; Tsc1*^*f/f*^ mice (right panel) showed an increase in the number of trabecular bones. N = 4 mice.(E) *LysM-Cre; Tsc1*^*f/f*^ mice (left panel) showed normal trabecular thickness, whereas *Ctsk-Cre; Tsc1*^*f/f*^ mice (right panel) showed an increase in the thickness of trabecular bones. N = 4 mice.(F) *LysM-Cre; Tsc1*^*f/f*^ mice (left panel) showed normal numbers of OCs, whereas *Ctsk-Cre;Tsc1*^*f/f*^ mice (right panel) showed an increase in the numbers of OCs. N = 6 mice.(G) TRAP staining on bone sections revealed that femurs of *LysM-Cre; Tsc1*^*f/f*^ mice showed normal number of TRAP-positive cells, whereas *Ctsk-Cre; Tsc1*^*f/f*^ mice showed an increase in the number of TRAP-positive cells. Scale bar, 50 μm.(H) *LysM-Cre;Tsc1*^*f/f*^ and *Ctsk-Cre;Tsc1*^*f/f*^ mice showed a decrease in the levels of urine DPD levels (upper panel) and serum levels of CTX (upper panel). N = 6 mice.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

Micro-CT analyses revealed that the mutant mouse femur displayed an increase in trabecular bone mass ([Figures 6](#fig6){ref-type="fig"}A--6E). The osteopetrotic phenotypes were largely rescued by inhibition of mTORC1 with rapamycin ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}B). Bone histomorphometry analysis confirmed these findings and revealed that *LysM-Cre; Tsc1*^*f/f*^ mice exhibited normal bone formation rate, bone mineralization rate, and the numbers of OCs in vivo ([Figure 6](#fig6){ref-type="fig"}F and data not shown). TRAP staining of bone sections confirmed that the numbers of OCs were similar between *LysM-Cre; Tsc1*^*f/f*^ and control mice ([Figure 6](#fig6){ref-type="fig"}G). However, *LysM-Cre; Tsc1*^*f/f*^ mice showed a decrease in bone resorption, demonstrated by a decrease in the serum levels of C-terminal telopeptide (CTX) and urine levels of DPD, two in vivo bone resorption markers ([Figure 6](#fig6){ref-type="fig"}H).

We then ablated *Tsc1* in differentiated OCs using *Ctsk-Cre* mice. These mice showed normal body weight and size and femur length ([Figure 6](#fig6){ref-type="fig"}B and data not shown), with an increase in trabecular bone volume and bone mineral contents ([Figures 6](#fig6){ref-type="fig"}C--6E). The osteopetrotic bone phenotypes in the *Ctsk-Cre; Tsc1*^*f/f*^ mice were more severe than those of *LysM-Cre; Tsc1*^*f/f*^ mice.

Surprisingly, the *Ctsk-Cre; Tsc1*^*f/f*^ mice showed an increase in the number of OCs ([Figure 6](#fig6){ref-type="fig"}F), which was confirmed by TRAP staining on bone sections ([Figure 6](#fig6){ref-type="fig"}G). However, the levels of urine DPD and serum CTX were decreased ([Figure 6](#fig6){ref-type="fig"}H), suggesting that OCs might be functionally incompetent. On the other hand, bone formation rate and bone mineralization rate were not altered in *Ctsk-Cre; Tsc1*^*f/f*^ mice (data not shown).

We also compared the vertebrae (L3 and L4) of *LysM-Cre; Tsc1*^*f/f*^ and *Ctsk-Cre; Tsc1*^*f/f*^ mouse lines against their respective control littermates using micro-CT, and found that bone mineral contents were not significantly altered in *LysM-Cre; Tsc1*^*f/f*^ mice, similar to the femur bone phenotypes ([Figure 6](#fig6){ref-type="fig"}A). However, the *Ctsk-Cre; Tsc1*^*f/f*^ mice showed greatly increased bone mineral contents ([Figure 6](#fig6){ref-type="fig"}A).

mTOR Activation Inhibited OC Differentiation, Fusion, and Activity {#sec2.8}
------------------------------------------------------------------

To determine the cellular basis of the decrease in bone resorption in *LysM-Cre; Tsc1*^*f/f*^ mice, we isolated bone marrow monocytes and carried out in vitro differentiation assays. mTOR was activated in monocyte cultures, yet its activation went down once undergoing differentiation ([Figure S7](#mmc1){ref-type="supplementary-material"}A). It was found that *Tsc1*^*−/−*^ monocytes showed increased proliferation rates ([Figure 7](#fig7){ref-type="fig"}A). Yet, in response to RANKL and M-CSF, the formation of TRAP-positive OCs and the expression of mature OC markers were decreased, while the number of TRAP-positive mononuclear cells was increased ([Figures 7](#fig7){ref-type="fig"}B and 7C). The OCs derived from *Tsc1*^*−/−*^ progenitors showed much fewer nuclei than WT OCs ([Figures 7](#fig7){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}B), accompanied by reduced levels of *DC-Stamp* and *OC-Stamp* ([Figure 7](#fig7){ref-type="fig"}D), which are required for OC fusion ([@bib20]). Moreover, differentiated osteoclasts derived from *Tsc1*-deficient monocytes showed a decrease in resorption activity on bone chips, which was associated with a decrease in the expression of enzymes involved in bone resorption ([Figures 7](#fig7){ref-type="fig"}D and 7E). These results suggest that mTOR activation inhibits osteoclast differentiation, fusion, and function, but promotes proliferation. As such, compromised differentiation may even increase the proliferation of OC progenitors. This may explain why the number of OC numbers in vivo was not significantly altered in *LysM-Cre; Tsc1*^*f/f*^ mice.Figure 7mTOR Activation Suppressed OC Differentiation, Fusion, and Resorption Activity, but Enhanced Proliferation(A) Monocytes isolated from *LysM-Cre; Tsc1*^*f/f*^ mice showed an increase in proliferation. The monocytes isolated from *WT* and *LysM-Cre; Tsc1*^*f/f*^ mice were cultured for 3 days in the presence of M-CSF and RANKL. Scale bar, 50 μm. Right panel: quantitation data. N = 4 independent experiments.(B) Ex vivo differentiation assays revealed that monocytes isolated from *LysM-Cre; Tsc1*^*f/f*^ mice showed a decrease in the number TRAP-positive OCs. Monocytes were isolated from the bone marrow and were induced to differentiate by M-CSF and RANKL. The cell cultures were stained for TRAP 5 days later. Bottom panel: quantitation data. Scale bar, 100 μm. N = 4 independent experiments.(C) Images of WT and *Tsc1*^*−/−*^ OCs. Scale bar, 50 μm.(D) qPCR analysis revealed that *Tsc1* ablation in *LysM*+ monocytes showed a decrease in the expression of OC differentiation markers and genes regulating OC fusion. N = 4 independent experiments.(E) *Tsc1*-deficient monocytes showed a decrease in bone resorption activity in vitro. Monocytes isolated from the *LysM-Cre; Tsc1*^*f/f*^ mice were induced to differentiate by M-CSF and RANKL, and then plated onto dentine slices. After 5 days, the slices were stained with toluidine blue and the resorption areas were measured (bottom panel). Red arrow, resorption pit. N = 3 independent experiments.(F) *Tsc1*^*−/−*^ monocytes showed a decrease in NF-κB activation during OC differentiation.(G) Ex vivo differentiation assays revealed that monocytes isolated from *Ctsk-Cre; Tsc1*^*f/f*^ mice showed a slight increase in TRAP-positive OCs. Monocytes were isolated from the bone marrow and were induced to differentiate by M-CSF and RANKL. The cell cultures were stained for TRAP 5 days later. Bottom panel: quantitation data. Scale bar, 100 μm. N = 5 independent experiments.(H) *Tsc1*-deficient OCs showed a decrease in bone resorption activity in vitro. Monocytes isolated from the *Ctsk-Cre; Tsc1*^*f/f*^ mice were induced to differentiate by M-CSF and RANKL for 3 days, and then plated onto dentine slices. After 5 days, the slices were stained with toluidine blue and the resorption areas were measured (bottom panel). Red arrow, resorption pit. Scale bar, 50 μm. N = 3 independent experiments.(I) CT images of TSC patients revealed sclerotic bone lesions (orange arrows) with roundish or irregular shape in the vertebral body and appendix of the cervical (a), thoracic (b), and lumbar (c) spine, as well as the sternum (d), rib (e), and pelvis (f).(J) The TSC patient serum samples showed an increase in the levels of osteocalcin. N = 20.(K) The TSC patient serum samples showed a decrease in the levels of CTX. N = 20.Error bars represent the SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

To further understand how mTOR activation affects OC differentiation, we looked at the signaling pathways known to control osteoclastogenesis. Western blot results showed that *Tsc1* deficiency led to a decrease in activation of the nuclear factor κB (NF-κB) pathway ([Figure 7](#fig7){ref-type="fig"}F). This is consistent with previous reports showing that mTOR activation downregulated NF-κB signaling ([@bib17], [@bib46]), the master regulator of OC differentiation, fusion, and activity.

We also isolated bone marrow monocytes from *Ctsk-Tsc1*^*f/f*^ mice and performed ex vivo differentiation assays. These cells only express Cre after differentiating into Ctsk-positive OCs, which would then lead to *Tsc1* deletion. We found that the number and size of TRAP-positive OCs were slightly increased in the mutant cultures ([Figure 7](#fig7){ref-type="fig"}G). However, differentiated OCs derived from *Ctsk-Cre; Tsc1*^*f/f*^ mice showed a decrease in bone resorption activity ([Figure 7](#fig7){ref-type="fig"}H). These results suggest that mTOR activation may promote proliferation and/or growth of differentiated osteoclasts, but interfere with their bone resorption activity. This may explain why *Ctsk-Cre; Tsc1*^*f/f*^ mice showed an increase in the number of OCs.

We also investigated the mechanisms underlying the bone resorption defects caused by *Tsc1* deficiency. Although autophagy has been reported to play a role in bone resorption ([@bib6], [@bib11]), we found that in OC cultures, autophagy markers p62 and LC3 were not significantly altered in the absence of Tsc1 ([Figure S7](#mmc1){ref-type="supplementary-material"}C). However, OCs showed an increase in size on bone sections of *Ctsk-Cre; Tsc1*^*f/f*^ mice but not of *LysM-Cre; Tsc1*^*f/f*^ mice ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Moreover, the number of ring-like actin structures was decreased in both mouse lines, with the decrease in *Ctsk-Cre; Tsc1*^*f/f*^ mouse bone sections being greater than that in *LysM-Cre; Tsc1*^*f/f*^ mice ([Figure S7](#mmc1){ref-type="supplementary-material"}E). These alterations may contribute to the resorption defects of *Tsc1*-deficient OCs and explain why *Ctsk-Cre; Tsc1*^*f/f*^ mice showed a greater osteopetrotic phenotype than *LysM-Cre; Tsc1*^*f/f*^.

TSC Patients Showed Increased Focal Bone Density Accompanied by Increased Bone Formation and Decreased Bone Resorption {#sec2.9}
----------------------------------------------------------------------------------------------------------------------

The above model animal studies indicate that mTOR signaling regulates bone size and quality during adolescent growth. We then wanted to validate these findings using TSC patient samples. TSC patients usually carry mutations in one allele of *TSC1* or *TSC2*, and loss of heterozygosity leads to benign tumor formation. We collected 64 TSC patients, 96.9% (62/64) of whom showed multiple sclerotic bone lesions in the vertebral body and appendix, the sternum, the rib, or the pelvis, on CT images ([Figure 7](#fig7){ref-type="fig"}I). We also collected serum samples from TSC patients between the ages 15 and 24 years to analyze bone formation marker osteocalcin and bone resorption marker CTX, and found that, compared with the age-matched normal group, TSC patients showed an increase in osteocalcin and a decrease in CTX ([Figures 7](#fig7){ref-type="fig"}J and 7K), suggesting that bone formation is increased while bone resorption is decreased in TSC patients.

Discussion {#sec3}
==========

This study, by analyzing mouse models with mTOR activated in BM-MSCs, monocytes, or their progenies, demonstrates that mTOR signaling regulates adolescent bone growth in size, mass, and mineral contents by acting on different cell types. mTOR activation in chondrocytes and OBs appears to be strong during adolescent growth and declines when reaching adulthood. mTOR activation increases bone radial growth, trabecular bone volume, and cortical bone thickness, mainly by promoting proliferation of *Prx1*+ BM-MSCs and increasing the pools of MSCs. However, mTOR activation decreases the length of long bones and bone mineralization, likely caused by impeded MSC chondrogenic and osteogenic differentiation, respectively ([Figure S7](#mmc1){ref-type="supplementary-material"}F). These findings suggest that mTOR signaling coordinates MSC proliferation and differentiation to regulate bone size and quality, and that expansion of the BM-MSC pool is an important step during bone growth. The mTOR signaling pathway may integrate the signals from growth factors, nutrients, and other pathways such as Pten or LKB1 to regulate bone growth in length ([@bib15], [@bib31], [@bib42]).

mTOR activation in MSCs appears to impede bone mineralization, indicating that mTOR activation does not mediate the anabolic effects of growth factors on bone mineral accretion. Instead, mTOR activation suppresses the catabolic effects of monocyte/OC in cell-autonomous manners. While several in vitro studies suggest that inhibition of mTOR with rapamycin impedes OC survival and differentiation ([@bib43]), our study provides genetic evidence that mTOR activation inhibits OC differentiation, fusion, and resorption activity, but promotes proliferation of monocytes and differentiated OCs, suggesting stage-specific effects for mTOR in osteoclastogenesis and function ([Figure S7](#mmc1){ref-type="supplementary-material"}F). OC differentiation and fusion defects may be caused by compromised NF-κB activation and decreased expression of cell fusion gene *DC-Stamp* and *OC-Stamp* ([Figure S7](#mmc1){ref-type="supplementary-material"}F), while OC resorption defects may be caused by mTOR-induced alteration in cell size and/or cytoskeleton. The more severe osteopetrotic phenotype of *Ctsk-Cre; Tsc1*^*f/f*^ than *LysM-Cre; Tsc1*^*f/f*^ mice can be explained by the difference in OC cell size and cytoskeleton ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E). The lack of increase in OC numbers in *LysM-Cre; Tsc1*^*f/f*^ mice could be caused by opposite and stage-specific effects of mTOR activation on OC proliferation and differentiation. It is worth noting that the peak bone mass is a net result of 10 weeks of bone formation and resorption, which may not be reflected by the bone parameters measured at week 10 of age or in vitro assays.

In addition, mTOR activation in MSCs, but not in OBs, plays a role in coupling to osteoclastogenesis. mTOR signaling in *Prx1+* MSCs alters the expression of M-CSF, OPG, and RANKL to inhibit osteoclastogenesis and bone resorption. Consistently, previous studies of mouse lines with *Tsc1* ablated in Osx- or osteocalcin-expressing OBs failed to detect significant alterations in bone resorption ([@bib7], [@bib13], [@bib39]). These findings support the concept that coupling exists between MSCs and monocytes in addition to the coupling between bone formation and resorption ([@bib9]). Thus, mTOR increases bone mineral contents by directly inhibiting OC differentiation and activity, and by altering MSCs-secreted RANKL and OPG.

Our studies reveal that more than 90% TSC patients of Han Chinese develop focal sclerotic bone lesions at different locations in the skeleton. Analysis of TSC patient serum samples confirmed that bone resorption marker is reduced, whereas bone formation marker is increased. While it is assumed that increased focal bone density is secondary to increased bone formation ([@bib44]), we found that, in mouse models, deletion of *Tsc1* in BM-MSCs or OBs led to a decrease in bone mineral contents. In contrast, deletion of *Tsc1* in monocytes especially in OCs led to a great increase in bone mineral contents. These data suggest that the increase in focal bone density in TSC patients is caused mainly by decreased bone resorption. Thus, sclerotic bone lesions should be deemed as "osteopetrotic lesions" in TSC patients.

Model animal and human sample studies have shown that hormone deficiency and undernutrition are the major factors affecting organ size, and which inhibit cell proliferation and cell size in the organ. Our current studies, together with the studies of OB- and chondrocyte-specific deletion of mTOR pathway molecules, indicate that mTOR signaling is an important regulator of bone size and quality. mTOR regulates bone size by acting on MSCs rather than OBs; its pro-proliferation activity in MSCs accounts for the bone radial growth and bone volume accrual, whereas its negative effects on MSC chondrogenic differentiation regulate bone growth in length. Therefore the coordination of MSC proliferation and differentiation controls bone growth in length and width.

In summary, we show that mTOR signaling regulates bone size mainly by coordinating MSC proliferation and differentiation, and bone quality mainly by suppressing OC differentiation and activity. Moreover, mTOR also plays a role in coupling MSCs and monocytes. Studies of TSC patient samples validated these findings. Collectively, our studies uncover multiple roles played by mTOR signaling in bone size and quality control.

Experimental Procedures {#sec4}
=======================

TSC Patients {#sec4.1}
------------

All the 64 TSC patients (38 women and 26 men; age range, 4--46 years; mean ± SD age, 26.1 ± 8.7 years) underwent CT examinations of the chest, abdomen, and pelvis using a SOMATOM Definition Flash scanner (Siemens Medical Systems) and a Discovery CT750 HD scanner (GE Medical Systems) with slice thickness of 5 mm and tube voltage of 120 kvp. The protocol for this study was approved by our institutional review board. All patients gave written consent.

Animal Studies {#sec4.2}
--------------

Animal work was carried out following the recommendations from the National Research Council Guide for the Care and Use of Laboratory Animals, with the protocols approved by the Institutional Animal Care and Use Committee of Shanghai, China (SYXK(SH)2011-0112). The *Prx1-Cre*, *Dermo1-Cr*e, *Osx-Cre*, *LysM-Cre*, *Ctsk-Cre*, and floxed *Tsc1* mouse lines were purchased from The Jackson Laboratory. For micro-CT and histomorphometry analysis, male mice at age 2.5 months were used, with the number of mice shown for each figure. For other mouse experiments, three mice (2.5-month-old male or female) were used.

Bone Histomorphometry and Three-Point Bending Experiment {#sec4.3}
--------------------------------------------------------

Bone histomorphometry was performed on undecalcified sections as described in the [Supplemental Information](#app2){ref-type="sec"}, and three-point bending experiments were conducted on a universal testing machine (RGM-2020, Shenzhen Reger Instrument) using fixed femurs.

Measurement of Serum Osteocalcin and CTX and Urine DPD {#sec4.4}
------------------------------------------------------

Fasting serum samples of TSC patients and normal individuals were collected to determine the levels of osteocalcin and CTX. Mouse urine samples were collected in the morning and were used to determine the levels of DPD and creatinine. The DPD values were normalized to creatinine.

BM-MSC Isolation and Differentiation {#sec4.5}
------------------------------------

BM-MSCs were isolated and induced to differentiate as described by [@bib9].

Monocyte Isolation and Differentiation and Resorption Pit Analysis {#sec4.6}
------------------------------------------------------------------

BM-MSCs were isolated and induced to differentiate as described by [@bib9].

qPCR {#sec4.7}
----

Total RNA was extracted by using TRIzol Regent (Invitrogen). The RNA was reverse transcribed using a Transcriptor Universal cDNA Master (Roche) according to the manufacturer\'s instructions. Real-time PCR was performed as described previously ([@bib9]). See [Supplemental Information](#app2){ref-type="sec"} for primer sequences.

Immunohistochemical Staining {#sec4.8}
----------------------------

See [Supplemental Information](#app2){ref-type="sec"} for detailed protocols.

Statistical Analyses {#sec4.9}
--------------------

Numerical data and histograms were expressed as the mean ± SD. Comparisons between two groups were analyzed using two-tailed unpaired Student\'s t test. p Values \< 0.05 were considered statistically significant. Analysis of mice was litter-based, and at least three litters were analyzed for every parameter. All experiments were repeated three to four times.
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